Hello map, there are several catalysts on the near to intermediate term horizon that could warrant a BO offer for BCRX -- the imminent approval and launch of berotralsat, the data and trials in new indications to be announced in Q3 and Q4 for 9930, and the Galidesivir trial results from Brazil coming in July-August.
I was wondering what you think about the NBC report of July 3 that they will soon reveal "a new study that shows promising results on therapeutics. They wouldn't describe the study because its disclosure could be market moving". Do you think they're talking about Galidesivir?
Do you have any thoughts on Galidesivir in comparison to other antivirals under trial for COVID, in particular EIDD-2801?